SEC Form 4 · accession 0002050167-26-000025
Maze Therapeutics, Inc. · MAZE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Atul Dandekar
Officer — CSBO
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 4:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001842295
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2026 | M | 12,500 | $0.00 | A | 38,750 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2,F3 | — | Sep 1, 2026 | M | 12,500 | D | — | — | Common Stock | 12,500 | 12,500 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- F2The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.
- F3These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.